GeNO has received two new US patents for its proprietary nitric oxide(NO)generation and delivery technology.
The US patent no.8,173,072 describes the conversion of nitrogen dioxide(NO2)to nitric oxide(NO),using the GeNO cartridge technology,in a gas stream to treat acute and chronic forms of pulmonary arterial hypertension.
The US patent no.8,187,544 describes a new method for scavenging traces of toxic nitrogen dioxide(NO2)from a gas stream prior to inhalation by a patient.
GeNO founder and president David Fine said the two new patents are important additions to the company's intellectual property portfolio,and extends patent protection into year 2030.
"It is unusual for a drug company already in Phase 2 clinical trials to have 18 years of patent protection on its key chemistry,"Fine added.
GeNO's nitric oxide delivery platform includes a gas cylinder system for hospital and outpatient use,a ventilator-based platform for intensive care unit use,and a pocket-sized ambulatory system for chronic outpatient use.
